Understanding RRAGD: A Potential Drug Target and Biomarker (G58528)

Target Name: RRAGD

NCBI ID: G58528

RRAGD

Understanding RRAGD: A Potential Drug Target and Biomarker

RRAGD (Research Report on Active Targets and G protein-coupled Receptors) is a drug target and biomarker that has been extensively studied in the field of pharmacology. RRAGD is a protein that is expressed in various tissues and cells in the body, including the brain, heart, and kidneys. It is a member of the G protein-coupled receptor (GPCR) family, which is a large family of transmembrane proteins that play a critical role in cellular signaling.

RRAGD is known for its role in the regulation of a variety of physiological processes in the body, including blood pressure, heart rate, and inflammation. It is also involved in the development and maintenance of the brain, and has been linked to a number of neurological disorders, including Alzheimer's disease and Parkinson's disease.

One of the key challenges in studying RRAGD is its high degree of cross-talk and redundancy. This is because RRAGD is expressed in many different tissues and cells in the body, and it is involved in the regulation of a wide range of physiological processes. In addition, RRAGD is a protein that is highly susceptible to changes in the cellular environment, such as changes in pH or the presence of certain molecules. This makes it difficult to studyRRAGD in a controlled and precise manner.

Despite these challenges, researchers have made significant progress in the study of RRAGD. In recent years, a number of studies have identified potential drug targets forRRAGD, and these targets have been further refined and validated. These drug targets include GPCR signaling pathways, which are involved in the regulation of a wide range of physiological processes, including blood pressure, heart rate, and inflammation.

In addition to its potential as a drug target, RRAGD is also a valuable biomarker for a number of diseases. For example,RRAGD has been used as a biomarker for a variety of neurodegenerative diseases, including Alzheimer's disease and Parkinson's disease. In addition,RRAGD has also been used as a biomarker for a number of other diseases, including cardiovascular disease and inflammation.

Overall, the study of RRAGD is an active area of research, with a number of potential drug targets and biomarkers being identified and studied. Further studies are needed to fully understand the role of RRAGD in the regulation of physiological processes and the development and maintenance of various diseases.

Protein Name: Ras Related GTP Binding D

Functions: Guanine nucleotide-binding protein that plays a crucial role in the cellular response to amino acid availability through regulation of the mTORC1 signaling cascade (PubMed:20381137, PubMed:24095279, PubMed:34607910). Forms heterodimeric Rag complexes with RRAGA or RRAGB and cycles between an inactive GTP-bound and an active GDP-bound form (PubMed:24095279). In its active form participates in the relocalization of mTORC1 to the lysosomes and its subsequent activation by the GTPase RHEB (PubMed:20381137, PubMed:24095279). This is a crucial step in the activation of the TOR signaling cascade by amino acids (PubMed:20381137, PubMed:24095279)

The "RRAGD Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about RRAGD comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets